Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

Publisher： Karger

E-ISSN： 1423-0097|138|1|59-66

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.138, Iss.1, 2005-09, pp. : 59-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression of a Human IgG4 Antibody, BAB2, with Specificity for the Major Birch Pollen Allergen, Bet v 1 in Escherichia coli: Recombinant BAB2 Fabs Enhance the Allergic Reaction

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 190-192

Karger

Access to resources Recommend Favorite

Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

By  

International Archives of Allergy and Immunology, Vol. 126, Iss. 1, 2001-10 ,pp. : 68-77

Karger

Access to resources Recommend Favorite

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite

A Model System to Study the Environment-Dependent Expression of the Bet v 1a Gene Encoding the Major Birch Pollen Allergen

By  

International Archives of Allergy and Immunology, Vol. 134, Iss. 1, 2004-05 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients

By  

ALLERGY, Vol. 70, Iss. 7, 2015-07 ,pp. : 795-804

John Wiley & Sons Inc

Access to resources Recommend Favorite